These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23571540)

  • 1. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
    Louie A; Liu W; Fikes S; Brown D; Drusano GL
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2788-92. PubMed ID: 23571540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.
    Bilal H; Bergen PJ; Kim TH; Chung SE; Peleg AY; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa.
    Oshima K; Nakamura S; Iwanaga N; Takemoto K; Miyazaki T; Yanagihara K; Miyazaki Y; Mukae H; Kohno S; Izumikawa K
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
    Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
    Rees VE; Yadav R; Rogers KE; Bulitta JB; Wirth V; Oliver A; Boyce JD; Peleg AY; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
    Landersdorfer CB; Rees VE; Yadav R; Rogers KE; Kim TH; Bergen PJ; Cheah SE; Boyce JD; Peleg AY; Oliver A; Shin BS; Nation RL; Bulitta JB
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets.
    Drusano GL; Lodise TP; Melnick D; Liu W; Oliver A; Mena A; VanScoy B; Louie A
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3406-12. PubMed ID: 21576431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model.
    Housman ST; Crandon JL; Nichols WW; Nicolau DP
    Antimicrob Agents Chemother; 2014; 58(3):1365-71. PubMed ID: 24342641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model.
    Zelenitsky SA; Karlowsky JA; Hoban DJ; Kabani A; Zhanel GG
    Chemotherapy; 1998; 44(1):1-6. PubMed ID: 9444401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
    Yadav R; Bulitta JB; Wang J; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
    Kidd JM; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2020 Jan; 75(1):149-155. PubMed ID: 31641765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a rabbit model of
    Gras E; Vu TTT; Nguyen NTQ; Tran VG; Mao Y; Tran ND; Mai NH; Dong OX; Jung DH; Iorio NLPP; Povoa HCC; Pinheiro MG; Aguiar-Alves F; Weiss WJ; Zheng B; Cheng LI; Stover CK; Sellman BR; DiGiandomenico A; Gibault L; Valour F; Diep BA
    Front Cell Infect Microbiol; 2023; 13():1297281. PubMed ID: 38149013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.
    Louie A; Liu W; VanGuilder M; Neely MN; Schumitzky A; Jelliffe R; Fikes S; Kurhanewicz S; Robbins N; Brown D; Baluya D; Drusano GL
    J Infect Dis; 2015 Apr; 211(8):1326-33. PubMed ID: 25362196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.
    Jaruratanasirikul S; Sriwiriyajan S; Punyo J
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1337-9. PubMed ID: 15793108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.
    Buyck JM; Tulkens PM; Van Bambeke F
    Antimicrob Agents Chemother; 2015 Jan; 59(1):258-68. PubMed ID: 25348528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia.
    Lodise TP; Sorgel F; Melnick D; Mason B; Kinzig M; Drusano GL
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1606-10. PubMed ID: 21300830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant.
    Drusano GL; Liu W; Fregeau C; Kulawy R; Louie A
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2266-73. PubMed ID: 19289521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.
    Tam VH; Schilling AN; Neshat S; Poole K; Melnick DA; Coyle EA
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4920-7. PubMed ID: 16304153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.
    Bretonnière C; Jacqueline C; Caillon J; Guitton C; Le Mabecque V; Miégeville AF; Villers D; Potel G; Boutoille D
    J Antimicrob Chemother; 2010 Nov; 65(11):2423-7. PubMed ID: 20858688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.